488 related articles for article (PubMed ID: 16787263)
21. Novel drugs targeting hypertension: renin inhibitors.
Danser AH
J Cardiovasc Pharmacol; 2007 Aug; 50(2):105-11. PubMed ID: 17703126
[TBL] [Abstract][Full Text] [Related]
22. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
23. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Neutel JM
Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
27. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
29. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
Atlas SA
J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
[TBL] [Abstract][Full Text] [Related]
30. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
31. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
32. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Major TC; Olszewski B; Rosebury W; Okerberg C; Carlson T; Ostroski R; Schroeder R; Kowala MC; Leadley R
Cardiovasc Drugs Ther; 2008 Dec; 22(6):469-78. PubMed ID: 18679781
[TBL] [Abstract][Full Text] [Related]
33. Renin inhibitors: optimal strategy for renal protection.
Schmieder RE
Curr Hypertens Rep; 2007 Nov; 9(5):415-21. PubMed ID: 18177590
[TBL] [Abstract][Full Text] [Related]
34. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
Katragadda S; Arora RR
Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
[TBL] [Abstract][Full Text] [Related]
35. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
Khoshghamat N; Jafari N; Toloue-Pouya V; Azami S; Mirnourbakhsh SH; Khazaei M; Ferns GA; Rajabian M; Avan A
Life Sci; 2021 Apr; 270():119118. PubMed ID: 33548284
[TBL] [Abstract][Full Text] [Related]
36. A vaccine for hypertension.
Ménard J
J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
[No Abstract] [Full Text] [Related]
37. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
38. Peptides as targets for antihypertensive drug development.
Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the renin-angiotensin system and the prevention of stroke.
Schrader J; Kulschewski A; Dendorfer A
Am J Cardiovasc Drugs; 2007; 7(1):25-37. PubMed ID: 17355164
[TBL] [Abstract][Full Text] [Related]
40. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
